| |
| |
|
| Insider
Information: |
Atlas Venture Associates Opportunity I, Llc |
| Relationship: |
10% Owner |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
10 |
|
| Direct
Shares |
10,748,022 |
|
|
Indirect Shares
|
27,238,687 |
|
|
| Direct
Value |
$57,124,257 |
|
|
|
Indirect Value
|
$83,775,198 |
|
|
| Total
Shares |
37,986,709 |
|
|
| Total
Value |
$140,899,455 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Replimune Group Inc |
REPL |
|
|
0 |
2019-11-18 |
1,100,000 |
Premium* |
|
|
Generation Bio Co. |
GBIO |
10% Owner |
2021-09-29 |
0 |
2021-09-29 |
8,279,484 |
Premium* |
|
|
Dyne Therapeutics, Inc. |
DYN |
10% Owner |
|
0 |
2020-09-21 |
1,608,785 |
Premium* |
|
|
Ikena Oncology, Inc. |
IKNA |
10% Owner |
2021-12-14 |
1,241,935 |
2021-03-30 |
874,634 |
Premium* |
|
|
Xilio Therapeutics, Inc. |
XLO |
10% Owner |
2024-02-08 |
2,019,563 |
2024-02-08 |
734,546 |
Premium* |
|
|
Vigil Neuroscience, Inc. |
VIGL |
10% Owner |
2022-01-11 |
0 |
2022-01-11 |
4,808,896 |
Premium* |
|
|
Day One Biopharmaceuticals, Inc. |
DAWN |
10% Owner |
2022-06-17 |
766,667 |
2022-06-17 |
8,217,352 |
Premium* |
|
|
Third Harmonic Bio, Inc. |
THRD |
10% Owner |
2022-09-19 |
594,096 |
|
0 |
Premium* |
|
|
Kymera Therapeutics, Inc. |
KYMR |
10% Owner |
2024-03-13 |
4,676,075 |
2024-03-13 |
828,830 |
Premium* |
|
|
Disc Medicine, Inc |
IRON |
10% Owner |
2024-01-10 |
1,449,686 |
2024-01-10 |
786,160 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
81 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| KYMR |
Kymera Therapeutics, Inc. |
10% Owner |
– – • |
2022-11-02 |
4 |
AS |
$30.02 |
$811,681 |
I/I |
(27,038) |
1,022,502 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
10% Owner |
– – • |
2022-11-02 |
4 |
AS |
$30.02 |
$2,899,362 |
D/D |
(96,581) |
5,440,875 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
10% Owner |
– – • |
2022-11-03 |
4 |
AS |
$30.00 |
$632,550 |
I/I |
(21,085) |
1,001,417 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
10% Owner |
– – • |
2022-11-03 |
4 |
AS |
$30.00 |
$2,259,360 |
D/D |
(75,312) |
5,365,563 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
10% Owner |
– – • |
2022-12-14 |
4 |
AS |
$30.28 |
$2,600,108 |
I/I |
(82,889) |
918,528 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
10% Owner |
– – • |
2022-12-14 |
4 |
AS |
$30.28 |
$9,287,505 |
D/D |
(296,077) |
5,069,486 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
10% Owner |
– – • |
2022-12-15 |
4 |
AS |
$30.00 |
$21,510 |
I/I |
(717) |
917,811 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
10% Owner |
– – • |
2022-12-15 |
4 |
AS |
$30.00 |
$76,830 |
D/D |
(2,561) |
5,066,925 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
10% Owner |
– – • |
2023-01-11 |
4 |
AS |
$29.96 |
$181,887 |
I/I |
(6,071) |
911,740 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
10% Owner |
– – • |
2023-01-11 |
4 |
AS |
$29.96 |
$649,623 |
D/D |
(21,683) |
5,045,242 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
10% Owner |
– – • |
2023-01-12 |
4 |
AS |
$30.29 |
$2,336,207 |
D/D |
(77,128) |
4,968,114 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
10% Owner |
– – • |
2023-01-12 |
4 |
AS |
$30.29 |
$654,022 |
I/I |
(21,592) |
890,148 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
10% Owner |
– – • |
2024-03-11 |
4 |
AS |
$42.77 |
$380,562 |
I/I |
(8,882) |
881,266 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
10% Owner |
– – • |
2024-03-11 |
4 |
AS |
$42.77 |
$1,812,586 |
D/D |
(42,302) |
4,925,812 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
10% Owner |
– – • |
2024-03-12 |
4 |
AS |
$41.94 |
$5,652,072 |
D/D |
(134,647) |
4,791,165 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
10% Owner |
– – • |
2024-03-12 |
4 |
AS |
$41.94 |
$1,186,741 |
I/I |
(28,271) |
852,995 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
10% Owner |
– – • |
2024-03-13 |
4 |
AS |
$42.19 |
$1,020,422 |
I/I |
(24,165) |
828,830 |
0 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
10% Owner |
– – • |
2024-03-13 |
4 |
AS |
$42.19 |
$4,859,993 |
D/D |
(115,090) |
4,676,075 |
0 |
- |
|
| REPL |
Replimune Group Inc |
|
– – – |
2019-11-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,100,000 |
|
- |
|
| THRD |
Third Harmonic Bio, Inc. |
10% Owner |
– – • |
2022-09-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,541,389 |
|
- |
|
| THRD |
Third Harmonic Bio, Inc. |
10% Owner |
– – • |
2022-09-19 |
4 |
A |
$0.00 |
$0 |
D/D |
7,066,470 |
594,096 |
0 |
- |
|
| THRD |
Third Harmonic Bio, Inc. |
10% Owner |
– – • |
2022-09-19 |
4 |
B |
$17.00 |
$5,100,000 |
D/D |
300,000 |
10,313,763 |
2.45 |
% |
|
| VIGL |
Vigil Neuroscience, Inc. |
10% Owner |
– – • |
2022-01-11 |
4 |
B |
$14.00 |
$7,490,000 |
I/I |
535,000 |
4,808,896 |
1.5 |
- |
|
| VIGL |
Vigil Neuroscience, Inc. |
10% Owner |
– – • |
2022-01-11 |
4 |
A |
$0.00 |
$0 |
I/I |
3,859,498 |
1,027,978 |
0 |
- |
|
| XLO |
Xilio Therapeutics, Inc. |
10% Owner |
– – • |
2021-10-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
26,315 |
|
- |
|
81 Records found
|
|
Page 3 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
